Molecular Mechanisms of Galidesivir as a Potential Antiviral Treatment for COVID-19
Abstract
No Abstract No Abstract No Abstract No Abstract
1. Rele S. Emerging outbreaks and epidemic threats: The practicality and limitations in the development and manufacturing of treatments for coronavirus (covid-19). Polymorphism 2020;4:45-52.
2. Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against sars-cov-2 rna dependent rna polymerase (rdrp): A molecular docking study. Life Sci 2020:117592.
3. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) and corona virus disease-2019 (covid-19): The epidemic and the challenges. Int J Antimicrob Agents 2020:105924.
4. Taylor R, Kotian P, Warren T, et al. Bcx4430–a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of ebola virus disease. J Infect Public Health 2016;9(3):220-6.
5. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of covid-19. J Pharm Anal 2020.
6. Basha SH. Corona virus drugs–a brief overview of past, present and future. Journal of PeerScientist 2020;2(2):e1000013.
7. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-ncov). Nature Publishing Group; 2020.
8. Velavan TP, Meyer CG. The covid‐19 epidemic. Tropical medicine & international health 2020;25(3):278.
9. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue bcx4430. Nature 2014;508(7496):402-5.
10. Zhang W, Stephen P, Thériault J-F, Wang R, Lin S-X. Novel coronavirus polymerase and nucleotidyl-transferase structures: Potential to target new outbreaks. J Phys Chem Lett 2020.
11. Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for covid-19: Drug repurposing approach. Life Sci 2020:117652.
2. Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against sars-cov-2 rna dependent rna polymerase (rdrp): A molecular docking study. Life Sci 2020:117592.
3. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) and corona virus disease-2019 (covid-19): The epidemic and the challenges. Int J Antimicrob Agents 2020:105924.
4. Taylor R, Kotian P, Warren T, et al. Bcx4430–a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of ebola virus disease. J Infect Public Health 2016;9(3):220-6.
5. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of covid-19. J Pharm Anal 2020.
6. Basha SH. Corona virus drugs–a brief overview of past, present and future. Journal of PeerScientist 2020;2(2):e1000013.
7. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-ncov). Nature Publishing Group; 2020.
8. Velavan TP, Meyer CG. The covid‐19 epidemic. Tropical medicine & international health 2020;25(3):278.
9. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue bcx4430. Nature 2014;508(7496):402-5.
10. Zhang W, Stephen P, Thériault J-F, Wang R, Lin S-X. Novel coronavirus polymerase and nucleotidyl-transferase structures: Potential to target new outbreaks. J Phys Chem Lett 2020.
11. Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for covid-19: Drug repurposing approach. Life Sci 2020:117652.
| Files | ||
| Issue | Vol 8, No 3 (Summer 2020) | |
| Section | Focus | |
| DOI | https://doi.org/10.18502/jpc.v8i3.4552 | |
| Keywords | ||
| No Keywords No Keywords No Keywords | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Ataei M, Hosseinjani H. Molecular Mechanisms of Galidesivir as a Potential Antiviral Treatment for COVID-19. J Pharm Care. 2020;8(3):150-151.
